Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 4.

Ledergerber, B; Costagliola, D; Lodwick, R; Torti, C; van Sighem, A; Podzamczer, D; Mocroft, A; Dorrucci, M; Masquelier, B; Günthard, H F; de Luca, A; Michalik, C (2013). Predictors of CD4+ T-Cell Counts of HIV Type 1-Infected Persons After Virologic Failure of All 3 Original Antiretroviral Drug Classes. Journal of Infectious Diseases, 207(5):759-767.

Cain, L E; Logan, R; Robins, J M; Sterne, J A C; Sabin, C; Bansi, L; Justice, A; Goulet, J; van Sighem, A; de Wolf, F; Bucher, H C; von Wyl, V; Esteve, A; Casabona, J; del Amo, J; Moreno, S; Seng, R; Meyer, L; Perez-Hoyos, S; Muga, R; Lodi, S; Lanoy, E; Costagliola, D; Hernan, M A (2011). When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. Annals of Internal Medicine, 154(8):509-515.

Lodwick, R K; Sabin, C A; Porter, K; Ledergerber, B; van Sighem, A; Cozzi-Lepri, A; Khaykin, P; Mocroft, A; Jacobson, L; De Wit, S; Obel, N; Castagna, A; Wasmuth, J C; Gill, J; Klein, M B; Gange, S; Riera, M; Mussini, C; Gutiérrez, F; Touloumi, G; Carrieri, P; Guest, J L; Brockmeyer, N H; Phillips, A N (2010). Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study. Lancet, 376(9738):340-345.

Lodwick, R; Costagliola, D; Reiss, P; Torti, C; Teira, R; Dorrucci, M; Ledergerber, B; Mocroft, A; Podzamczer, D; Cozzi-Lepri, A; Obel, N; Masquelier, B; Staszewski, S; García, F; De Wit, S; Castagna, A; Antinori, A; Judd, A; Ghosn, J; Touloumi, G; Mussini, C; Duval, X; Ramos, J; Meyer, L; Warsawski, J; Thorne, C; Masip, J; Pérez-Hoyos, S; Pillay, D; van Sighem, A; Lo Caputo, S; Günthard, H; Paredes, R; De Luca, A; Paraskevis, D; Fabre-Colin, C; Kjaer, J; Chêne, G; Lundgren, J D; Phillips, A N (2010). Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years. Archives of Internal Medicine, 170(5):410-419.

This list was generated on Tue Sep 26 03:53:58 2017 CEST.